Selective calcium channel antagonists
AssigneeNorthwestern University
InventorsDalton J. Surmeier, JR., Richard B. Silverman, Soo Sung Kang, Garry Cooper
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., Cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.
Claims20
A method of selectively inhibiting a Cav1.3-calcium ion channel, comprising contacting said Cav1.3-calcium ion channel with a compound of the formula:
- wherein R1 comprises a cycloalkane or bicycloalkane, and R2 comprises a substituted aryl ring group.
The method of claim 4, wherein said phenyl group comprises a single non-hydrogen substituent selected from the group consisting of:
- F, Cl, Br, CF3, CO2H, CN, NO2, MeO, and Me.
A method of treating and/or preventing a neurodegenerative disorder comprising administering to a subject a Cav1.3-selective calcium ion channel antagonist of the formula:
- wherein R1 comprises a cycloalkane or bicycloalkane, and R2 comprises a substituted aryl ring group.
A pharmaceutical composition comprising a Cav1.3-selective calcium ion channel antagonist of the formula:
- wherein R1 comprises a cycloalkane or bicycloalkane, and R2 comprises a substituted aryl ring group. In some embodiments, R1 comprises cyclohexane, cyclopentane, or bicyclo[2.2.1]heptanes (norbornane). In some embodiments, R2 comprises a substituted phenyl group. In some embodiments, the phenyl group comprises a single non-hydrogen substituent selected from the group consisting of:
- F, Cl, Br, CF3, CO2H, CN, NO2, MeO, and Me.
Dependencies are inferred from the claim text.